Research Study

News Articles for Research Study top ^
Successful Dose Response Further Confirms Phase 3 Trial Design Company to Hold Conference Call at 8:30 a.m. ET on Monday, January 5, 2015 MENLO PARK, Calif.
Sign-up for Versartis Announces Positive 12 Month Data for VRS-317 from Ongoing Extension Study investment picks
Statistically Significant Improvements in Key Cardiac Parameter in Fabry Patients Previously Naïve to Therapy CRANBURY, N.J., Jan.
Sign-up for Amicus Therapeutics Announces Positive Phase 3 Data on Cardiac Endpoints From Fabry Monotherapy Study 011 and Long Term Extension Study investment picks
Landmark Study Reconfirms Oncotype DX® Stratifies DCIS Patient Risk Additional Presentations Include Positive Results from Genomic Health's First Liquid Biopsy Study in Breast Cancer REDWOOD CITY, Calif.
Sign-up for 2014 San Antonio Breast Cancer Symposium to Feature Oncotype DX® DCIS Study in Press Program on Friday, December 12 investment picks
2014 San Antonio Breast Cancer Symposium Presentation Underscores the Value of Oncotype DX® as Chemotherapy Guide SAN ANTONIO , Dec.
Sign-up for Genomic Health Announces Presentation of First Prospective Outcomes Study of Oncotype DX® Breast Cancer Test investment picks
The International Breast Cancer Study Group (IBCSG), Breast International Group (BIG), and Merck, known as MSD outside the United States and Canada, today announced the opening of the PANACEA study, a global collaborative study exploring a new way to treat HER2+ breast cancer that has become resistant to the current standard of care.
Sign-up for International Breast Cancer Study Group, Breast International Group and Merck Announce Opening of International PANACEA Study of Patients with HER2+ Breast Cancer investment picks
Analysis of 285 Patient Subgroup Shows an Impressive Statistically Significant 59% Improvement in Overall Survival Results at Two Years Post Treatment Continue to Support Protocol for Ongoing Phase III OPTIMA Trial LAWRENCEVILLE, N.J. , Feb.
Sign-up for Celsion Announces Updated Overall Survival Data from HEAT Study of ThermoDox® in Primary Liver Cancer investment picks
2014/12/17 VANCOUVER, BC--(Marketwired - December 17, 2014) - In the news release, "Midas Gold Files Technical Report for Golden Meadows Preliminary Feasibility Study on SEDAR," issued Tuesday, December 16, 2014, by Midas Gold Corp (TSX: MAX) (OTCQX: MDRPF), we are advised by the company that the headline of the press release should read "Midas Gold Files Technical Report for Stibnite Gold Preliminary Feasibility Study on SEDAR" rather than, "Midas Gold Files Technical Report for Golden Meadows Preliminary Feasibility Study on SEDAR" and that the header title of the company's boilerplate should read "About Midas Gold and the Stibnite Gold Project" rather than "About Midas Gold and the Golden Meadows Project" as originally issued.
Sign-up for CORRECTION - Midas Gold Files Technical Report for Golden Meadows Preliminary Feasibility Study on SEDAR investment picks
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a developer of innovative RNA-based therapeutics, today announced data through Week 168 from Study 202, a Phase IIb open-label extension study of eteplirsen in patients with Duchenne muscular dystrophy (DMD). After more than three years of treatment, results of the 6-minute walk test (6MWT) at 168 weeks showed continued ambulation across all patients evaluable on the test, however all patients showed a decline in distance walked on this measure since the week 144 timepoint.
Sign-up for Sarepta Therapeutics Reports Long-Term Outcomes through 168 Weeks from Phase IIb Study of Eteplirsen in Duchenne Muscular Dystrophy investment picks
AT&T Receives Highest Ranking Four Times in a Row DALLAS , Feb.
Sign-up for AT&T Ranks Highest in J.D. Power 2015 Wireless Purchase Experience Study investment picks
- Largest Analysis of Data from Patients with Primary Biliary Cirrhosis NEW YORK, Dec.
Sign-up for Intercept Announces Publication of Meta-Analysis From the Global PBC Study Group in Gastroenterology investment picks
Alkermes plc (NASDAQ: ALKS) today announced topline results from FORWARD-1, one of a series of supportive clinical studies in the comprehensive FORWARD phase 3 pivotal program for ALKS 5461, a once-daily, oral investigational medicine with a novel mechanism of action for the adjunctive treatment of major depressive disorder (MDD). The FORWARD-1 study was designed to evaluate the safety and tolerability of two titration schedules of ALKS 5461.
Sign-up for Alkermes Announces Positive Results From Study of ALKS 5461 for Treatment of Major Depressive Disorder investment picks
MENLO PARK, Calif., Dec.
Sign-up for Versartis to Hold Conference Call to Discuss VRS-317 Clinical Update From Ongoing Extension Study investment picks
2014/12/12 SAN FRANCISCO, CA and TOKYO, JAPAN --
Sign-up for Data Presented From Phase 2 Study of Enzalutamide in Advanced Androgen-Receptor Positive, Triple-Negative Breast Cancer investment picks
Gilead Sciences, Inc. (NASDAQ: GILD) today announced long-term follow-up results from the registration studies further describing the duration of response, progression-free survival (PFS) and safety profile for Zydelig ® (idelalisib) in relapsed patients with chronic lymphocytic leukemia (CLL) and two types of indolent non-Hodgkin lymphoma (iNHL). The findings are being presented this week at the Annual Meeting of the American Society of Hematology (ASH). Zydelig is indicated in the United States as monotherapy for patients with relapsed follicular B-cell non-Hodgkin lymphoma (FL) and small lymphocytic lymphoma (SLL) who have received at least two prior systemic therapies, and in combination with rituximab for patients with relapsed CLL for whom rituximab alone would be considered appropriate therapy due to comorbidities.
Sign-up for Gilead Presents Follow-up Data from Zydelig Registrational Studies in Patients with Chronic Lymphocytic Leukemia, Follicular Lymphoma and Small Lymphocytic Lymphoma investment picks
The randomized, double-blind, placebo-controlled Phase III study with RHB-102 for acute gastroenteritis and gastritis (the GUARD study) is underway in the U.S., with a planned enrollment of 320 patients Top-line results from the Phase III GUARD study are expected during H2/2015 RedHill recently submitted a European Marketing Authorization Application (MAA) seeking approval of RHB-102 , newly branded as BEKINDA ™ , for cancer patients suffering from chemotherapy and radiotherapy-induced nausea and vomiting TEL-AVIV, Israel, Dec.
Sign-up for RedHill Biopharma Announces First Patients Enrolled in the Phase III Study of RHB-102 (BEKINDA(TM)) for Gastroenteritis and Gastritis investment picks
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced that ASPIRA, a Phase 2 study of duvelisib, an oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, with background methotrexate in patients with moderate-to-severe rheumatoid arthritis (RA) did not meet its primary endpoint.
Sign-up for Infinity Reports Topline Results from Phase 2 Study of Duvelisib in Rheumatoid Arthritis investment picks
Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that the U.S. Food and Drug Administration (FDA) verbally informed the Company in a preliminary call of a partial clinical hold, under which the Company is cleared to begin a modified multiple-dose study of ARC-520 in patients with chronic hepatitis B infection.
Sign-up for Arrowhead Provides Update on IND for ARC-520 Phase 2b Study investment picks
Cognitive vehicles and industry co-creation with consumers will become commonplace by 2025, but not fully autonomous driving DETROIT , Jan.
Sign-up for New IBM Study Details The Future Of Automotive Industry investment picks

Premium Membership: Features and Benefits
Wide-Moat Screener for Stocks

Put a moat around your portfolio. Sniff out the most promising opportunities that can ride through any market.

Gold Medalist Screener for Funds

Narrow the available universe of 5000 funds to the top rated gold and silver. Then, sort for manager tenure, expense ratio, risk and return to create your own index-beating fund watchlist.

Thousands of Premium Analyst Reports

While many of our competitors measure a stock's worth with a computer program, Morningstar's staff of 150+ analyst sift through company fillings, financial data and a wealth of other sources to deliver an unvarnished review of any investment. In fact, twelve Morningstar analysts have been recognized by WSJ as "Best on the Street" in the US.

Premium Portfolio Monitor

Make decisions with confidence. Load your investments into our research center and automatically connect to all our proprietary tools and data points.


Never be without critical research. Free with your active membership, take our Premium data and guidance wherever you go with Morningstar for iPad®, iPhone®, and Android apps.

Morningstar's Guarantee

We're looking out for you. If after your 14-day free trial, you find that a Morningstar Premium membership is not for you, cancel any time and we'll be happy to refund the unused portion - no questions asked.

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Research Study
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: Research Storage  |  Next: Research Subscription